Showing results (11-20 of 39) with videos related to
Sort By:
Pageof 4
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1993
Local production of interleukin-6 during acute rejection in human renal allograftsM H Raasveld, J J Weening, J M Kerst, et al.Scandinavian Journal of Haematology|July 1, 1986
Platelet volume analysis in thrombocytopenia in relation to bleeding tendencyJ van der Lelie, J M Kerst, E van der Vorm, et al.The Journal of Urology|June 11, 2005
Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancerJ A Nieuwenhuijzen, A Bex, W Meinhardt, et al.Experimental Hematology|August 7, 1998
Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+)I S Weimar, N Miranda, E J Muller, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 1, 1989
Binding characteristics of dimeric IgG subclass complexes to human neutrophilsT W Huizinga, M Kerst, J H Nuyens, et al.Experimental Hematology|November 1, 1992
Combined measurement of growth and differentiation in suspension cultures of purified human CD34-positive cells enables a detailed analysis of myelopoiesisJ M Kerst, I C Slaper-Cortenbach, A E von dem Borne, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2008
A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)C Theodore, I Skoneczna, I Bodrogi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2015
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)N I Cherny, R Sullivan, U Dafni, et al.Cancer Immunology, Immunotherapy : CII|May 21, 2005
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II studyJ M Kerst, A Bex, H Mallo, et al.Experimental Hematology|November 1, 1993
Interleukin-6 is a survival factor for committed myeloid progenitor cellsJ M Kerst, I C Slaper-Cortenbach, C E van der Schoot, et al.Pageof 4